- Home
- RGC vs INBX Comparison
RGC vs INBX Comparison
Compare RGC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- INBX
- Stock Information
- Founded
- RGC 2014
- INBX 2010
- Country
- RGC Hong Kong
- INBX United States
- Employees
- RGC N/A
- INBX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- INBX Health Care
- Exchange
- RGC Nasdaq
- INBX Nasdaq
- Market Cap
- RGC 105.3M
- INBX 218.9M
- IPO Year
- RGC 2021
- INBX 2020
- Fundamental
- Price
- RGC $4.86
- INBX $12.74
- Analyst Decision
- RGC
- INBX Hold
- Analyst Count
- RGC 0
- INBX 1
- Target Price
- RGC N/A
- INBX N/A
- AVG Volume (30 Days)
- RGC 8.8K
- INBX 74.4K
- Earning Date
- RGC 10-25-2024
- INBX 11-14-2024
- Dividend Yield
- RGC N/A
- INBX N/A
- EPS Growth
- RGC N/A
- INBX N/A
- EPS
- RGC N/A
- INBX 119.38
- Revenue
- RGC N/A
- INBX $1,568,000.00
- Revenue This Year
- RGC N/A
- INBX N/A
- Revenue Next Year
- RGC N/A
- INBX N/A
- P/E Ratio
- RGC N/A
- INBX $0.11
- Revenue Growth
- RGC N/A
- INBX 19.24
- 52 Week Low
- RGC $3.03
- INBX $10.80
- 52 Week High
- RGC $32.44
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- RGC 44.96
- INBX 32.23
- Support Level
- RGC $4.75
- INBX $13.57
- Resistance Level
- RGC $5.21
- INBX $16.83
- Average True Range (ATR)
- RGC 0.30
- INBX 0.94
- MACD
- RGC 0.04
- INBX -0.21
- Stochastic Oscillator
- RGC 23.87
- INBX 1.68
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.